Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Wiser Advisor Group LLC

Wiser Advisor Group LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 53.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 230 shares of the medical research company’s stock after selling 265 shares during the period. Wiser Advisor Group LLC’s holdings in Thermo Fisher Scientific were worth $142,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of TMO. Silvercrest Asset Management Group LLC increased its position in shares of Thermo Fisher Scientific by 2.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 45,630 shares of the medical research company’s stock worth $26,521,000 after acquiring an additional 1,053 shares during the last quarter. Waverly Advisors LLC lifted its stake in Thermo Fisher Scientific by 7.1% in the first quarter. Waverly Advisors LLC now owns 2,386 shares of the medical research company’s stock valued at $1,387,000 after buying an additional 158 shares during the last quarter. Kennedy Capital Management LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter worth about $11,657,000. Industrial Alliance Investment Management Inc. lifted its position in Thermo Fisher Scientific by 2.4% in the 1st quarter. Industrial Alliance Investment Management Inc. now owns 853 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 20 shares during the last quarter. Finally, In Depth Partners LLC boosted its stake in Thermo Fisher Scientific by 2.8% during the 1st quarter. In Depth Partners LLC now owns 13,262 shares of the medical research company’s stock valued at $7,708,000 after purchasing an additional 356 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Royal Bank of Canada cut their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Stephens started coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of NYSE TMO traded up $1.63 during mid-day trading on Monday, reaching $514.89. The company had a trading volume of 202,037 shares, compared to its average volume of 1,489,582. The stock has a fifty day moving average of $575.70 and a two-hundred day moving average of $580.20. Thermo Fisher Scientific Inc. has a 12-month low of $480.57 and a 12-month high of $627.88. The company has a market capitalization of $196.95 billion, a price-to-earnings ratio of 32.18, a PEG ratio of 3.39 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period last year, the company earned $5.69 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.